Pfizer drops £69bn AstraZeneca takeover bid

clock

US drugs giant Pfizer has withdrawn its £55 a share, £69bn takeover bid for UK pharmaceutical firm AstraZeneca.

It said: "Following the AstraZeneca board's rejection of the proposal, Pfizer announces that it does not intend to make an offer," the BBC reports. AstraZeneca's chairman, Leif Johansson, said it would "continue building on the momentum we have already demonstrated as an independent company." AstraZeneca had fiercely resisted the bid, backed by some politicians. It rejected a final offer from Pfizer earlier this month, saying the proposal undervalued the company and its "attractive prospects". Nevertheless, in recent weeks some AstraZeneca shareholders had said they wanted the f...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Equities

Investment, Talks Webinar: Changing global patterns can bring new opportunities

Investment, Talks Webinar: Changing global patterns can bring new opportunities

Join Investment Week and Capital Group on the 22nd May at 11am

Hardeep Tawakley
clock 08 May 2025 • 1 min read
Webinar: What's next for equities?

Webinar: What's next for equities?

How can investors navigate the impact of tariffs and a rapidly changing global economy?

Investment Week
clock 08 May 2025 • 1 min read
Will a tech shake-up stop the rise of passives?

Will a tech shake-up stop the rise of passives?

'That kind of built-in safety net is hard to beat'

Laura Suter
clock 18 February 2025 • 2 min read